ERNA - Eterna Therapeutics Inc.

0.285
-0.022   -7.719%

Share volume: 501,811
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.14%

PREVIOUS CLOSE
CHG
CHG%
$0.31
-0.02
-0.07%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
39%
Profitability 35%
Dept financing 41%
Liquidity 46%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-4.36%
1 Month
-7.65%
3 Months
-78.08%
6 Months
-77.02%
1 Year
5.24%
2 Year
-3.39%
Key data
Stock price
$0.28
P/E Ratio 
0.00
DAY RANGE
$0.28 - $0.31
EPS 
$3.00
52 WEEK RANGE
$0.14 - $2.86
52 WEEK CHANGE
$5.24
MARKET CAP 
8.400 M
YIELD 
N/A
SHARES OUTSTANDING 
7.849 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-29-2025
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$712,319
AVERAGE 30 VOLUME 
$3,533,547
Company detail
CEO: Matthew Angel
Region: US
Website: brooklynitx.com
Employees: 10
IPO year: 2006
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Brooklyn ImmunoTherapeutics, Inc. engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology.

Recent news